Shuttle Pharmaceuticals reported that it received formal notice from Nasdaq that it is not in compliance with Nasdaq Listing Rule 5250 as a result of the company’s failure to timely file its quarterly report on Form 10-Q for the period ended June 30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHPH:
- Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
- Shuttle Pharmaceuticals opens enrollment in Ropidoxuridine trial
- Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
- Shuttle Pharmaceuticals Holdings Inc trading halted, news pending
- Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE